Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone

Behav Brain Res
01 Jan 2021
https://pubmed.ncbi.nlm.nih.gov/32905811/

Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management  (Abstract)

Molecules
11 Sept 2020
https://pubmed.ncbi.nlm.nih.gov/32932935/

Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study (Abstract)

Front Pharmacol
18 Sept 2020
https://pubmed.ncbi.nlm.nih.gov/33071790/

Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review (Abstract)

J Am Dent Assoc
December 2020
https://pubmed.ncbi.nlm.nih.gov/33228882/

Background: The authors aimed to evaluate the efficacy of low-dose naltrexone in the management of chronic pain conditions and determine its potential use in orofacial pain management.

Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels

Arthritis Rheum
February 2013
https://pubmed.ncbi.nlm.nih.gov/23359310/​​​​​​​

Low-Dose Naltrexone: An Inexpensive Medicine for Many Ills?

Medscape Medical News
11 Mar 2020
https://www.medscape.com/viewarticle/926611?src=WNL_trdalrt_201027_MSCPEDIT&uac=267476HJ&impID=2640101&f

Low-Dose Naltrexone Gaining Recognition as Chronic Pain Treatment

Pain News Network, 23 Nov 2020
https://www.painnewsnetwork.org/stories/2020/11/23/low-dose-naltrexone-gains-recognition-as-chronic-pain-treatment

Galyn Forster, MS, LPC - Treating Psychiatric Disorders with LDN; Case Studies I (2017 Conference) (LDN, low dose naltrexone)

LDN Research Trust on Vimeo.

Dr Asher Goldstein’s presentation on Pain at The 2019 Pain Seminar.

Dr Goldtsein talks about the Opioid Epidemic in America, stating that over 1.4 million Americans misused opioids in 2017.